ArticleFrontiers in immunology2026

Vitiligo secondary to immunosuppressants: a pharmacovigilance study of the FDA Adverse Event Reporting System.

Ying Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.